Dr Reddy's sitting on $30 m cashpile

Of the $125.4 million proceeds of the issue made in April 2001, the company has thus far utilised $74.1 million to liquidate debt and other liabilities.

As per the data available in its latest annual report, Dr Reddy's has invested Rs 92.7 crore in the last fiscal in its Indian and overseas subsidiaries, taking the total investments to Rs 156.6 crore.

The investments include Rs 56.67 crore for acquiring the UK-based BMS Laboratories and its wholly owned subsidiary Meredian Healthcare Ltd.

These are now called Dr. Reddy's Laboratories (EU) Ltd and Dr Reddy's Laboratories (UK) Ltd, respectively.

The other major investments of Dr Reddy's in 2002-03 include Rs 24.99 crore in Aurigene Discovery Technologies to fund research activities at Bangalore and Boston, US.

Further, a Rs 9 crore extended to loss making subsidiary Compact Electric Ltd was converted into equity last fiscal.

According to the ADS issue prospectus, Dr Reddy's had broadly indicated $30 million for drug discovery and development and $ 75 million for acquisitions and/or the establishment of marketing operations in US.

The company has, however, made it clear in the prospectus, that it will have significant flexibility in applying the net proceeds of ADS issue.